Compare INDO & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INDO | CODX |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | Indonesia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.1M | 15.6M |
| IPO Year | 2019 | 2017 |
| Metric | INDO | CODX |
|---|---|---|
| Price | $3.14 | $5.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $67.50 |
| AVG Volume (30 Days) | ★ 454.0K | 73.4K |
| Earning Date | 03-18-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,293,625.00 | $507,892.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.10 | $4.84 |
| 52 Week High | $7.95 | $46.50 |
| Indicator | INDO | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 96.47 |
| Support Level | $2.95 | $0.17 |
| Resistance Level | $3.21 | $0.30 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | -0.00 | 0.33 |
| Stochastic Oscillator | 66.79 | 95.56 |
Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. The company is an independent energy company engaged in the oil and gas business and holds two oil and gas assets through its subsidiaries in Indonesia: The Kruh Block and the Citarum Block. It has also identified a potential third exploration block known as the Rangkas area. . Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.